Myelodysplastic Syndrome (MDS) Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center
|16139B||A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes.
|16840A||E2905: Randomized Phase III Trial
Comparing the Frequency of Major Erythroid
Response (MER) to Treatment with
Lenalidomide (Revlimid) Alone and in
Combination with Epoetin Alfa (Procrit) in
Subjects with Low- or
Intermediate-1 Risk MDS and Symptomatic
|09-130-B||A University of Chicago Leukemia Registry Protocol.
|10-064-B||Molecular characterization of hematopoietic malignancies
|12-0153||A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
|IRB14-0331||A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
|IRB14-0702||A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team